Originally published In Press as doi:10.1074/jbc.M202316200 on June 7, 2002
J. Biol. Chem., Vol. 277, Issue 45, 42514-42522, November 8, 2002
Chemical Identification of a Low Abundance Lysozyme
Peptide Family Bound to I-Ak Histocompatibility
Molecules*
Carlos
Velazquez
§,
Ilan
Vidavsky¶,
Koen
van der
Drift¶,
Michael L.
Gross¶, and
Emil R.
Unanue
From the
Department of Pathology and Immunology,
Washington University School of Medicine and the ¶ Department of
Chemistry, Washington University, St. Louis, Missouri 63110
Received for publication, March 9, 2002, and in revised form, June 4, 2002
 |
ABSTRACT |
The processing by antigen-presenting cells (APC)
of the protein hen egg-white lysozyme (HEL) results in the selection of
a number of peptide families by the class II major histocompatibility complex (MHC) molecule, I-Ak. Some of these
families are expressed in very small amounts, in the order of a few
picomoles/109 APC. We detected these peptides from an
extract of class II MHC molecules by using monoclonal anti-peptide
antibodies to capture the MHC-bound peptides prior to their examination
by HPLC tandem mass spectrometry. Here, we have identified several
members of a family of peptides encompassing residues 20-35, which
represent less than 1% of the total HEL peptides. Binding analysis
indicated that the core segment of the family was represented by
residues 24-32 (SLGNWVCAA). Asn-27 (shown in boldface) is the main
MHC-binding residue, mapped as interacting with the P4 pocket of the
I-Ak molecule. Analysis of several T cell hybridomas
indicated that three residues contacted the T cell receptor: Tyr-23
(P
1), Leu-25 (P3), and Trp-28 (P5). The HEL peptides isolated
from the APC extract were sulfated on Tyr-23, but further analysis
showed that this modification did not occur physiologically but
took place during the peptide isolation.
 |
INTRODUCTION |
To understand the nature of the CD4 T cell response to peptides in
a protein antigen, it is important to explain the basis for peptide
selection during processing. It requires, therefore, the identification
and quantification of the peptides that are selected by the class II
MHC1 molecules of the
antigen-presenting cells (APC). There are two major difficulties with
the identification of the class II MHC-bound peptides. The first is
that peptides are selected as families, which comprise many members; a
family is characterized by having a core sequence that interacts with
the P1 to P9 anchoring sites of the MHC binding groove and flanking
residues (1-7). The flanking residues vary greatly in length and
determine the number of members in a family. The flanking residues
contribute to the affinity of binding to class II molecules and to the
half-life of the peptide-MHC complex on the surface of APC (7-10).
Additionally, flanking residues can have a marked effect on the T cell
recognition (11, 12). The length of the peptides and their size
heterogeneity, however, make it difficult to purify them for analysis
as well as to predict binding motifs. A second difficulty with the
analysis of class II-bound peptides is that their amounts vary greatly
among the various families, by as much as 250-fold (13). Thus,
characterization of these heterogeneous peptide families is
particularly difficult.
Studying the HEL protein as an antigen, we identified most of the
segments selected for presentation by the I-Ak molecule
(14). Most of the HEL-specific T cell response was directed to the HEL
epitopes: HEL-(18-33), HEL-(31-47), HEL-(48-63), and HEL-(115-129)
(14). In a previous study, we identified the naturally processed
peptides of the HEL-(48-63) family (DGSTDYGILQINSRWW) (4), the most
abundant epitope, occupying up to 10-20% of the total class II MHC
molecules (15). However, we had to develop a peptide immunoaffinity
capture technique to isolate and characterize the lower abundance HEL
peptide families (3). This approach consisted of purifying and
concentrating the HEL peptides from a class II MHC peptide extract by
using an anti-HEL peptide-specific monoclonal antibody (mAb) followed
by their identification by HPLC/electrospray tandem mass spectrometry
(ESI-MS). This method allowed the identification and quantification of
the HEL-(31-47 peptide family (AAKFESNFNTQATNRNT) (3). The anti-HEL
peptide-specific antibodies were also used by applying ELISA methods to
quantitate the peptides in the class II MHC peptide extract (13).
In this article we report our studies of a second HEL peptide family
that stimulates T cells, although it is represented in very low amounts
on the APC class II molecules, i.e. ~100 copies of
20-35-mer peptide/105 I-Ak molecules (13).
Despite the 20-35 family occurring in extremely small amounts, we were
able to characterize five members by using the antipeptide capture technique.
 |
MATERIALS AND METHODS |
Cell Lines--
The murine B cell lymphoma lines M12.C3.F6
(M12-Ak) (16) expressing class II I-Ak
molecules and the M12.C3.F6 cell line transfected with a membrane form
of HEL (M12-Ak mHEL) were used (17). Three other C3F6 cell
lines expressing mutations of HEL were generated as described
previously (18). The lines contained alanine substitutions for Ser-24,
Asn-27, or Cys-30. All cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 5% heat-inactivated normal calf serum and were tested for levels of I-Ak and HEL before
their analysis.
Synthesis of Peptides--
Unmodified HEL peptides and
phosphorylated peptides were synthesized by Fmoc chemistry
(N-(9-fluorenyl)methoxycarbonyl; model 432A; Applied
Biosystems, Foster City, CA) and purified by reverse-phase HPLC (600E;
Waters, Milford, MA). The sequences of all peptides were confirmed
subsequently by mass spectrometry. HEL-(20-35) peptides
sulfated at either Tyr-20 or Tyr-23 were purchased from Synpep (Dublin, CA).
Production of mAb--
A mAb (15B7-1B5, IgG1) that
recognizes the HEL-(18-33) epitope (DNYRGYSLGNWVCAAK) was generated as
described previously (13). (HEL-(18-33) had been identified previously
with synthetic peptides as one segment that stimulated T cells.) This
mAb recognizes the free HEL peptide in solution or bound to an ELISA
plate. Briefly, the anti-HEL-(18-33) peptide mAb was generated by
repeated immunizations of CB.17 mice with synthetic HEL-(18-33)
peptide coupled to OVA protein using bromoacetyl succinimide
(Sigma). A cysteine was added to the carboxyl terminus of the
peptide to facilitate coupling to OVA, and a serine was substituted for
cysteine at residue 30. Mice were injected subcutaneously with 400 µg
of HEL-(18-33) peptide-OVA protein in complete Freund's adjuvant
(Difco, Detroit, MI) followed by two subcutaneous injections in
incomplete Freund's adjuvant (400 µg of HEL-(18-33)
peptide-OVA/immunization) at 2-week intervals. Finally, 3 days before B
cell fusion, the mice were boosted intravenously with 100 µg of
HEL-(18-33) peptide-OVA in sterile saline solution. Spleen cells from
immunized mice were fused with the myeloma fusion partner P3 × 63.Ag8 using polyethylene glycol 1500 (Roche Molecular Biochemicals) by
standard procedures. The B cell hybridomas were selected by testing
supernatants in ELISA plates coated with the HEL-(18-33) peptide, and
the positive supernatants were screened immediately by binding to free
HEL-(18-33) peptide in a competitive ELISA (13). The 15B7-1B5 B
hybridoma was selected and injected into pristane (Sigma)-treated SCID
(severe combined immunodeficient) mice. The 15B7-1B5 mAb was purified
from ascites using protein A-Sepharose (Sigma).
Isolation of I-Ak-associated Peptides--
Class II
I-Ak molecules were isolated from ~0.8-3.2 × 1010 (~20-60 liters of cell culture) B lymphoma cells
M12-AkmHEL or control B cell line M12-Ak fed
with exogenous HEL by immunoaffinity chromatography, as described previously (3, 13), but with some modifications to improve the peptide
isolation method. Briefly, the APCs were lysed with 40 mM
MEGA-8/MEGA-9 detergents (Sigma) in phosphate-buffered saline in the
presence of enzyme inhibitors (1 mM phenylmethylsulfonyl fluoride, 10 mM iodoacetamide, and 20 µg/ml leupeptin).
The suspension was centrifuged at 8,000 rpm for 30 min at 4 °C. The
I-Ak molecules were isolated from the supernatant using the
anti-I-Ak mAb 40 F, which recognizes the I-Ak
-chain (19). Specifically, the supernatant was incubated with mAb
40 F coupled to cyanogen bromide-activated Sepharose beads (Sigma)
overnight at 4 °C. Then, the Sepharose beads were loaded into a
chromatography column (Bio-Rad) and washed extensively with a large
volume of phosphate-buffered saline at pH 7.2 until the OD readings at
280 nm and 214 nm of the washing solution were equal to the OD reading
of the blank solution; the excess salt in the column was removed with
5-10 column volumes of Milli-Q water. After the washes, the 40 F mAb
beads were transferred to another chromatography column (Bio-Rad) but
without the porous polymer bed support. Glass wool fiber was placed in
the column opening to retain the beads, and the
I-Ak·peptide complexes were subsequently eluted with
0.1% trifluoroacetic acid. The replacement of the bed support
was made to minimize the loss of peptides. To recover all of the
I-Ak material, the flow-through was incubated with new
40 F mAb beads again, and the class II molecules were eluted as
mentioned above. Peptides were separated from I-Ak
molecules by filtration through a Centripep (YM-10) centrifugal filter
device (Amicon, Beverly, MA). The peptide extract was dried down and
reconstituted in a volume of 5 ml with 0.1 M Tris-HCl, pH
7.4, and incubated with 0.8-1.1 ml of a 50% v/v of 15B7-1B5 mAb
(anti-HEL-(18-33)) coupled to cyanogen bromide-activated Sepharose beads (Sigma) overnight at 4 °C. After an overnight rotation, the
beads were loaded into a chromatography column (Bio-Rad) and washed extensively with a large volume of phosphate-buffered saline, and the excess salt in the column was removed with distilled water. After the washes, the 15B7-1B5 beads were transferred into a 5-ml syringe (BD Pharmingen). Glass wool fiber was placed in the syringe opening to retain the beads. The bound peptides were eluted with 0.1%
trifluoroacetic acid into prelubricated tubes (Costar, Corning Glass).
Four fractions were collected at 1.0 ml/fraction, and each fraction was
dried down and reconstituted in a total volume of 20-60 µl of a 2%
acetronitrile, 0.6% acetic acid and analyzed by mass spectrometry. To
ensure the complete removal of the peptide, the extract from the
I-Ak was neutralized with 1.0 M Tris-HCl, pH
7.4, and passed two to four more times through the 15B7-1B5 mAb
column. The HEL peptides were eluted from the mAb column with 0.1%
trifluoroacetic acid as described above. The recovery of peptide
was estimated using synthetic peptides to range from 50-75%.
Analysis by Mass Spectrometry--
Analysis of the class II
I-Ak peptides and synthetic peptides were carried out using
the HPLC Finnigan LCQ Classic and LCQ Deca electrospray tandem mass
spectrometers (Finnigan, San Jose, CA). The peptide samples were
reconstituted in 20-60 µl of 2% acetronitrile, 0.6% acetic acid
solution, and 5-15 µl of the sample were injected into the capillary
reverse-phase HPLC (a Zorbac C18 0.3 × 25 mm column; Micro-Tech,
Sunnyvale, CA) connected on-line to the electrospray mass spectrometer.
A flow rate of 4.5 µl/min into the electrospray source was maintained
with either a 600-MS Waters HPLC system (for the LCQ classic) or a
Micro-Tech Scientific Ultra Plus HPLC system (for the LCQ Deca). The
gradient used was as follows: solvent A (acetic acid in water) was kept
constant at 0.6%; solvent B (acetronitrile) was kept constant at 2%
for the first 5 min, increased to 15% in the next 5 min, and then to
60% in the next 50 min. The capillary temperature was kept at
150 °C. The scan range used was m/z 700-1400,
and three "microscans" were averaged to give one scan. Acquisition
was started 10 min after the commencement of the LCQ run. For
collision-induced dissociation (CID) experiments, precursor ions were
selected with a width of m/z 2.5 and activated
using collision energies ranging between 25 and 35% of the maximum
collision energy. For the LC and CID analyses, 200 fmol of the
synthetic peptides was used. Sequence analysis was performed using an
automated protein data base sequencing program (SEQUEST; John Yates,
University of Washington, Seattle) on an ICIS work station
(Finnegan), which compares the experimental production of the mass
spectra to the predicted ion mass spectra.
Peptide Binding Assays--
I-Ak molecules expressed
in baculovirus were used in a binding competition assay with a standard
radiolabeled peptide (20). I-Ak molecules were expressed
containing a peptide from the invariant chain, the CLIP peptide,
tethered to a linker segment having a thrombin-sensitive sequence. The
purified molecules were treated with thrombin at the same time that a
standard I-125 radiolabeled HEL peptide was added. (The peptide was
HEL-(52-61) with an added tyrosine at the amino terminus:
YDYGILQINSR). The time of incubation was 18-24 h; all reactions were
carried out at pH 5.5. The amounts of peptide bound about 20-30% of
input cpm. Variable amounts of nonlabeled peptides were tested in the
reactions, and the amounts that inhibited 50% (IC50) of
the binding of the standard radiolabeled peptide to I-Ak
were estimated.
Generation of T Cell Hybridomas and T Cell Assay--
T cell
hybridomas were generated by immunizing B10.BR mice with 10 nmol of HEL
protein emulsified with complete Freund's adjuvant (Difco) in the
footpad (14). A cell suspension was prepared from the draining lymph
nodes at day 7 after immunization. After 72 h of restimulation
in vitro with HEL-(18-33) peptide, T cells were fused with
the thymoma cell line BW5147


. T
hybridoma lines specific to the HEL-(18-33) peptide were selected on
the basis of peptide sensitivity and subcloned by limiting dilution. T
hybridoma assays were performed in 96-well tissue culture plates. T
cell hybridomas were added at 105 cells/well and incubated
with the B cell lymphoma line M12-Ak at 5 × 104 cells/well in the presence of different doses of HEL
protein or test peptide in a total volume of 200 µl; the
mixture was then incubated for 20 h at 37 °C with 5%
CO2. Subsequently, each well was assayed for levels of IL-2
using the IL-2-dependent cell line, CTLL. In a total volume
of 200 µl, 100 µl of supernatant was transferred to 20,000 CTLL
cells and cultured for 18 h. In the last 8 h, the cells were
pulsed with 0.5 µCi/well of [3H]thymidine.
Studies on Tyrosine Sulfation of HEL Peptides--
For a control
on the finding of sulfation of the peptide, I-Ak molecules
containing a synthetic peptide were added to a control cell lysate from
M12-Ak cells. I-Ak molecules expressed in
baculovirus (20) or isolated from APC (21) were used to make the
HEL-(20-35) peptide·I-Ak complex in vitro.
Similar results were obtained with both I-Ak preparations.
I-Ak molecules (300 µg) were incubated with 75 nmol of
synthetic HEL-(20-35) peptide in the presence of 50 mM
L-lysophosphatidylcholine and 1 M
2-N-morpholinoethane sulfonic acid at pH 5.5. The mix
reaction was incubated for 7 days at room temperature. The
HEL-(20-35)·I-Ak complex was added into a control
M12-Ak cellular lysate obtained from ~1010
M12-Ak cell lysed with 100 ml of MEGA 8/MEGA 9 solubilization buffer (108 cell equivalents/1 ml of
lysate). The isolation of the HEL-(20-35) peptide and its MS analysis
was performed as described above.
To evaluate the tyrosylprotein sulfotransferase (TPST) activity in the
M12.Ak cellular lysate, we used as a high-affinity
substrate for TPST, the acidic random polymer poly(Glu-Ala-Tyr)
(EAY 6:3:1, Mr 43,000 (Sigma)) (22) and as
sulfate donor, radioactive 3'-phosphoadenosine 5'-phosphosulfate
([35S]PAPS; PerkinElmer Life Sciences). The assay mixture
contained, in a final volume of 100 µl, 10 µl of M12-Ak
cellular lysate (5 × 108 cells/ml of solubilization
buffer), 20 µM [35S]PAPS, and 100 µM EAY. The reaction was incubated at 4 °C overnight and stopped with 2× SDS-sample buffer. Samples were analyzed by SDS-PAGE. Alternatively, the samples were precipitated with 20% trichloroacetic acid, and the incorporated radioactivity in the samples
was determined by liquid scintillation counting.
 |
RESULTS AND DISCUSSION |
To isolate and quantify the naturally processed forms of the
HEL-(18-33) epitope, we used the 15B7-1B5 specific to the HEL peptide
sequence from residues 18-33: DNYRGYSLGN-WVCAAK (13). This mAb
recognizes the HEL-(18-33) peptide both in solution and bound to an
ELISA plate and had been used to determine the abundance of this HEL
peptide on I-Ak molecules isolated from an APC line that
expresses a membrane form of HEL, M12-AkmHEL.
The HEL-(18-33) epitope (13) was expressed in low abundance on the
M12-AkmHEL APC, i.e. about 9 pmol of
peptide/5.6 × 106 APC. In this study, we isolated the
natural sequence, represented mostly by the 20-35 peptide, and
identified the amino acid residues responsible for anchoring the
peptide to the I-Ak molecules as well as those residues
that interact with the T cell receptor (TCR). We call attention to the
finding that the peptide was found sulfated, but this change took place
following its isolation.
Identification of Naturally Processed Forms of the HEL-(18-33)
Epitope--
We first extracted all of the peptides bound to class II
molecule I-Ak of the M12.Ak mHEL line. Then the
members of the HEL-(18-33) peptide family were isolated and
concentrated by immunoaffinity chromatography using the 15B7-1B5 mAb
specific to the peptide-(18-33). The eluted peptides were analyzed by
mass spectrometry. In the mass chromatogram of the purified peptides,
we observed several peptides eluting at retention times between 28 and
30 min. The molecular ions were doubly charged ions [M + 2H]2+ with an m/z of 932.5, 990.0, and 1047.1. These corresponded to the peptides HEL-(20-35)
(YRGYSLGNWVCAAKFE), HEL-(19-35) (NYRGYSLGNWVCAAKFE), and HEL-(18-35)
(DNYRGYSLGNWVCAAKFE), respectively (Fig.
1). The most abundant member of this HEL
family was peptide-(20-35). The amino acid sequence of the
HEL-(20-35) peptide was determined by MS/MS analysis; a search
conducted in the protein sequence data base, using the SEQUEST program,
identified this sequence as corresponding to the HEL peptide.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
Identification of the naturally processed
HEL-(20-35) peptide family on M12.Ak mHEL cells.
Class II molecules were purified from 1.7 × 1010
M12.Ak mHEL cells, and the peptides bound to
I-Ak molecules were isolated using the anti-HEL-(18-33)
peptide mAb column. The mass spectrum of the naturally processed HEL
peptides shows several doubly charged [M + 2H] ions with an
m/z of 932.5, 990.0, and 1047.1 corresponding to
peptides HEL-(20-35), HEL-(19-35), and HEL-(18-35), respectively. In
addition to those peptides, the mass spectrum shows another three ions
with 40 mass units higher than the HEL peptides.
|
|
In addition to these HEL peptide masses, we observed three doubly
charged ions with 40 m/z units higher that the
HEL peptides and with identical retention times. The
m/z values of these ions were
972.52+, 1030.52+, and 1087.52+
(Fig. 1). This m/z difference indicates that the
HEL peptides were likely post-translationally modified by either a
phosphate or sulfate group, either of which would add a mass of 80 Da
to the peptide or protein (for doubly charged ions these modifications change the m/z of peptides by 40). Although we
used larger m/z mass ranges for many of our
experiments (i.e. m/z 700-1400) than that shown in Fig. 1, we found no signals of greater intensity than
those of the putative sulfated peptides and the peptides themselves.
The HEL-(20-35) Epitope Is Modified by a Sulfate Group--
The
amino acid sequence of the HEL-(20-35) epitope (YRGYSLGNWVCAAKFE)
contains three potential residues to be modified: the tyrosines at
positions 20 and 23, which could be modified by either sulfation or
phosphorylation, and a serine residue at position 24, which could be
phosphorylated. We ruled out the phosphorylation at serine 24 as a
possible modification because the recognition of the anti-HEL-(18-33)
mAb (15B7-1B5) used to isolate this HEL peptide family depends on an
unmodified serine 24 (data not shown). Therefore, the only two possible
modification sites on the HEL-(20-35) epitope are the two tyrosine
residues at positions 20 and 23.
To identify the nature of the modification present on the naturally
processed HEL-(20-35) epitope, we isolated from the
M12-AkmHEL line the HEL-(20-35) peptide family. The most
abundant member of this family (HEL-(20-35) peptide) was submitted to
CID in the ion trap. The resulting product-ion spectrum was compared
with those of synthetic sulfated or phosphorylated HEL-(20-35)
peptides. The product-ion spectra of the naturally processed HEL
peptide and the synthetic modified peptides are very similar (Fig.
2). In contrast, the CID spectrum of the
synthetic phosphorylated HEL-(20-35) peptide is significantly
different. This observation strongly indicates that the HEL-(20-35)
peptide isolated from APC was sulfated (not phosphorylated) on
tyrosine. In subsequent MS experiments, we identified the tyrosine at
position 23 as the amino acid modified by the sulfate group. Synthetic
peptides with sulfated tyrosine at either residue 20 or 23 were added
to the natural peptide and submitted for analysis; the addition of the Tyr-20 sulfated peptide resulted in two peaks (retention times of 28.6 and 29.5 min) that were base line-resolved, whereas addition of
the Tyr-23 sulfated peptide only yielded one peak (29.5 min).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
The naturally processed HEL-(20-35) peptide
is modified by a sulfated group. A, naturally processed
HEL-(20-35) peptide family was isolated from M12-Ak mHEL
APC, and the HEL-(20-35) peptide (the most abundant member of this
family) was submitted to CID in the Finnigan LCQ ion trap mass
spectrometer. The resulting product ion spectrum was compared with the
CID spectra obtained with synthetically sulfated HEL-(20-35) peptide
at position 23 (B) and with synthetically phosphorylated
HEL-(20-35) peptide at position 23 (C). Note that the CID
spectra of the naturally processed HEL peptide and the synthetically
sulfated HEL-(20-35) peptide are very similar.
|
|
Interestingly, when we analyzed the mass spectrum of the synthetic
HEL-(20-35) peptide that was sulfated at Tyr-23, we observed two ions
with m/z values of 932.52+ and
972.52+. Those m/z values correspond
to the unsulfated and sulfated forms of the HEL-(20-35) peptide,
respectively. This facile loss of sulfur trioxide that accompanies
electrospray ionization of a sulfated peptide was described previously
(23, 24) and it is due to the weak bond between the sulfate group and
peptide (25) and the thermochemical stability of SO3.
Furthermore, there were a considerable number of fragment ions
generated in the CID of the synthetic phosphorylated peptide,
which were not present either in the product-ion spectrum of the
naturally processed peptides or in that of the synthetically sulfated
peptides (Fig. 2). The loss of SO3 from sulfated peptides
occurs so readily that the typical fragmentation of the peptide chain
to give b and y ions, for example, is not
competitive. The stronger linkage to phosphate, however, allows the
other fragmentations to compete with the loss of the phosphate group.
Others have pointed out this contrast between sulfated and
phosphorylated peptides (23-25), and the difference appears to be general.
The loss of 98 atomic mass units (either
H3PO4 or HPO3 and H2O)
that is observed for the phosphorylated standard is often viewed as
difficult or impossible from peptides that contain phosphorylated Tyr,
as exemplified in a recent report (26). Nevertheless, there is ample
precedent for this loss from singly charged phosphopeptides, beginning
with some of the earliest reports of matrix-assisted laser desorption
ionization (MALDI)/MS of these materials (27-29). The precedent that
is most relevant to our observations is that reported by DeGnore and
Qin (30), who showed that doubly charged 20-mer peptides phosphorylated
on Tyr can lose 98 Da in CID to produce abundant product ions. It is
likely that the loss takes place in two steps, the first being that of
HPO3 and the second that of H2O. This loss of
98 Da, however, is not general for peptides that contain
phosphotyrosine, and the rules governing its occurrence are not known.
We emphasize that the mass spectrum of the naturally processed
HEL-(20-35) peptide family also showed the sulfated and unsulfated versions of the HEL-(20-35), HEL-(19-35), and HEL-(18-35) peptides (Fig. 1). All of these sulfated and unsulfated forms showed identical retention times in the HPLC preceding the MS, indicating that the
signal for the unsulfated HEL peptides in this mass spectrum was
because of the loss of the sulfur trioxide from the sulfated peptide
during the ionization process in the mass spectrometer and not the
presence of both sulfated and unsulfated HEL peptides in the original sample.
In subsequent MS experiments, we showed that the peptide remaining
after loss of SO3 is indeed HEL-(20-35) by comparing its product-ion spectrum (MS/MS) with that of the unknown. The spectrum of
the synthetic standard HEL-(20-35) gave an abundant but incomplete series of b ions and a less abundant and incomplete series
of y ions (relative abundance is shown in parentheses):
b152+ (100%),
b14 (5%), b13 (55%),
b12 (20%), b11 (15%),
b10 (35%), b9 (15%),
b6 (10%), b5 (5%), and
b4 (5%); y14 (5%),
y10 (5%), y9 (2%),
y8 (5%), y6 (15%), and
y4 (5%).
The naturally processed peptide, which we found in lesser
quantities than the standard, gave a spectrum that agrees well with that of the standard (nd indicates "not detected'):
b152+ (100%),
b14 (5%), b13 (35%),
b12 (20%), b11 (10%),
b10 (20%), b9 (10%),
b6 (nd), b5 (nd), and
b4 (nd); y14 (3%),
y10 (5%), y9 (nd),
y8 (nd), y6 (10%), and
y4 (nd).
Some of the low abundance ions could not be detected because the
(chemical) noise level in certain m/z regions of
the naturally processed species' spectra was poorer than that of the
standard. Nevertheless, the agreement between spectra and the sequence
coverage add confidence that the naturally processed peptide is
sulfated HEL-(10-35).
In experiments not shown, we also examined HEL peptides from the
M12.C3.F6 line cultured in the presence of exogenous HEL. We identified
HEL-(20-35), HEL-(19-35), and HEL-(18-35) as observed in the
M12.Ak mHEL APCs experiment (Fig. 1). The most abundant
member of this HEL peptide family was the peptide HEL-(20-35). We also
identified peptide-(20-36) and -(20-37) but in lesser abundance. All
of the HEL peptides carried a post-translational modification of 80 atomic mass units, as indicated by the two signals separated by
40 m/z in the mass spectra.
Tyrosine Sulfation of the HEL-(20-35) Epitope is an Artifact
Generated during the Peptide Isolation Procedure--
Tyrosine
sulfation is a post-translational modification of secretory, plasma
membrane, and lysosomal proteins occurring in all multicellular
eukaryotic organisms (31, 32). This modification is catalyzed by the
TPST, an integral membrane glycoprotein residing in the trans-Golgi
network (33). TPST uses PAPS as the sulfate donor in the sulfate
transfer reaction. Based on the Trans-Golgi localization of TPST, we
were surprised by the isolation of sulfated HEL peptides from APC fed
with exogenous HEL protein. Therefore, we evaluated whether the
tyrosine sulfation of this HEL peptide was occurring physiologically or
was generated during the peptide isolation procedure. We formed
in vitro the unsulfated HEL-(20-35) peptide·I-Ak complex. When the 20-35 peptide was
isolated from this complex and examined by MS, we found the correct
mass of the unsulfated peptide to be 932.92+ (Fig.
3A). We next added the complex
into a control M12-Ak cellular lysate, at the cell
equivalent concentration used to obtain the previous results. The mass
spectrum of the recovered HEL peptide showed the expected mass ion for
the sulfated HEL-(20-35) peptide, m/z of 972.5 (Fig. 3B). The presence of sulfate group in the HEL peptide
was confirmed by MS/MS analysis. Indeed, other studies using
radioactive PAPS to evaluate the TPST activity in the
M12-Ak cellular lysate indicated the presence of such
activity in the extract (Fig. 4). (We
also examined, using HPLC/MS, whether the HEL protein isolated from the
APCs M12-Ak mHEL or from M12-Ak fed with
exogenous HEL was sulfated on tyrosine residues. We did not find any
evidence of sulfation on either or both protein samples, indicating
that under physiological conditions in APC, the HEL protein was not
sulfated.)

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 3.
Tyrosine sulfation of the HEL-(20-35)
epitope is generated during the peptide isolation procedure.
Unsulfated HEL-(20-35) peptide·I-Ak complex was
generated in vitro and added into a control
M12-Ak cellular lysate. A, mass spectrum
of the HEL-(20-35) peptide isolated from the unsulfated HEL-(20-35)
peptide·I-Ak complex before being added into the control
cellular lysate. Note the presence of unsulfated HEL-(20-35) peptide,
mass ion 932.9. B, mass spectrum of the HEL-(20-35) peptide
isolated from the unsulfated HEL-(20-35) peptide·I-Ak
complex after added into the control cellular lysate. The HEL
peptide·Ak complex was incubated overnight at 4 °C.
Note the presence of sulfated HEL-(20-35) peptide, mass ion
972.5.
|
|

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 4.
Presence of TPST activity in the
M12.Ak cellular lysate. The TPST activity in the
cellular M12-Ak lysate was measured using the EAY polymer
(poly(Glu-Ala-Tyr)) as a substrate for TPST. EAY (100 µM)
was incubated with 10 µl of M12-Ak cellular lysate
(5 × 108 cell equivalent/ml of solubilization buffer)
in the presence of radioactive [35S]PAPS (20 µM) and cold PAP (100 µM). The total volume
of the assay mixture was 100 µM). The total volume of the
assay mixture was 100 µl. The TPST activity is represented as the
incorporated radioactivity in dpm.
|
|
Finally, we generated a panel of T cell hybridomas that specifically
recognize sulfated peptide. These T hybridomas, developed by immunizing
mice with sulfated HEL-(20-35) peptide, were selected in
vitro for reactivity to the sulfated HEL peptide. We used these T
hybridomas as a read-out system to evaluate whether the sulfated HEL
peptides were presented on APC. None of these T cells reacted with APC
cultured in HEL or in APCs, which express the HEL protein as a
membrane-bound protein, confirming that under physiological conditions
epitope-(20-35) was not sulfated. Thus, the tyrosine sulfation of the
HEL-(20-35) family of peptides was generated during the peptide
isolation procedure, resulting from the presence of TPST in the extract.
Binding Studies--
The binding of the most abundant peptide,
HEL-(20-35), to I-Ak molecules was tested. In 17 different
experiments, the IC50 averaged 1.4 µM.
Although the degree of binding varied about 30% depending on the
preparation, it was highly consistent within experiments in which
various mutant peptides were tested. Fig.
5 summarizes experiments testing
HEL-(20-35) peptide in which several residues were changed to alanines
in order to see the effects on MHC binding. Notably, changing Asn-27 to
Ala resulted in a drop in binding of 200%, an average from six
different experiments. No other amino acid when changed to alanine
reduced binding significantly. However, a change of Cys-30 to Ala
increased binding by 72%.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 5.
Analysis of the binding of Ala-substituted
HEL-(20-35) peptide to I-Ak molecules. Several
residues of the HEL-(20-35) peptide were substituted to alanines, and
the IC50 was estimated. The effect of the Ala substitution
on HEL-(20-35) peptide binding is represented as the % of increase or
% of reduction of peptide binding with respect to the HEL-(20-35)
peptide. The graph summarizes the results of 4-8
experiments for each substitution. The mean IC50 was 1.4 µM in 17 different experiments testing 20-35.
N.D., no determination.
|
|
The crystal structure of I-Ak containing the HEL-(48-62)
peptide indicated the interactions of the peptide amino acid residues with the various binding sites on I-Ak, as well as the
relationship between amino acids that served to anchor the peptide to
I-Ak with those that stimulated the T cell (34). The
central or core sequence occupied the stretch from P1 to P9. An acidic
residue at P1, Asp-52, was favored for strong binding as well as for
peptide selection. At P4, small hydrophobic residues or
asparagines were favored. As with most MHC-displayed peptides, amino
acids that contacted the TCR were positioned at P2, P5, and P9.
Extrapolating this information to peptide-(20-35), we mapped the P1 to
P9 stretch to residues 24-32 (Tables I
and II). As will be noted below, changing Leu-25 and Trp-28 to Ala did
not affect binding but reduced entirely the T cell response; these two
residues were TCR contact residues. In
residues 24-32, Leu-25 is at P2, a TCR contact, Asn-27 at P4,
the main MHC contact, and Trp-28 at P5, another TCR contact. P1 is
occupied by Ser-24, contributing little to binding energy.
View this table:
[in this window]
[in a new window]
|
Table I
T cell contact residues of the HEL-(20-35) epitope
This table summarizes the data shown in Fig. 7. , no response or very
poor response at the highest peptide concentration tested (10 µM). ND, not determined.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Summary of HEL peptides
This table indicates the three major members of the peptide families
studied thus far. The P1 to P9 sequence is underlined, and the main
residues responsible for binding are in bold type. Residues that are
underlined are those identified as TCR contacts. Binding studies are
found in Refs. 3 and 8. Quantitation
studies were reported in Ref. 13.
|
|
Fig. 6 shows the results of one
experiment in which the binding of HEL-(20-35) was compared with
HEL-(24-32); there was a drop in binding from 2.1 to 5.6 µM. Testing the HEL-(24-32) peptide, we found that a
Ser-24 to Ala change reduced binding, whereas the change of Asn-27 to
Ala resulted in a complete lack of interaction.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 6.
Analysis of the binding of truncated
HEL-(20-35) peptide to I-Ak molecules. The HEL
peptide 24-32 (SLGNWVCAA) is the core sequence that binds to the
I-Ak molecule. The IC50 of truncated
HEL-(24-32), Ala-substituted HEL-(24-32), and HEL-(20-35) peptide
are shown. The Ala changes are in bold letters. Note that
the HEL-(24-32) Ala-27 peptide does not bind to
I-Ak molecules, indicating that Asn-27 is the main
MHC-binding residue.
|
|
We also examined the selection of the HEL-(20-35) family from
cell lines expressing HEL in which either the Ser-24 or the Asn-27 had
been changed to alanines. The cell lines were tested for their
presentation of the chemically dominant peptide-(48-63) or -(20-35)
(Fig. 7). Very clearly, the presentation
of peptide-(48-63) was not affected by the changes, which was not an
unexpected result. However, the changes in either residue 24 or 27 profoundly affected presentation. (Note below, however, that such
changes did not affect T cell responses.) Not shown are the results of
changing Cys-30 to Ala, which had no effect on presentation.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 7.
C3F6 lines with mutations at Ser-24 or Asn-27
present poorly to 20-35-reactive T cell hybridomas. The two
lines, M12.AkmHEL, Ala-24, and
M12.AkmHEL, Ala-27, presented equally to 3A9, a T cell
hybridoma that recognizes 48-61. However, the response by 3F12, a T
cell hybridoma that recognizes 20-35, was poor. Note that in this
figure, 3F12 recognized peptides with alanine substitutions at either
residue 24 or 27. Thus, the poor response to the lines was interpreted
as an indication of a smaller selection of the peptide.
|
|
In summary, these results, shown in Figs. 5-7, indicate the important
role of Asn-27 in binding as well as in peptide selection from
processing. They also indicate the importance of Ser-24 and, as
indicated in Fig. 6, the contribution of residues outside the central
core to binding strength. That is to say, peptide-(20-35) bound better
than -(24-32). Previously, we had established that residues outside
the central core, as in the case of peptide-(52-61), contributed to
binding strength, as a result of main chain interactions with residues
in the binding site of I-Ak (8, 34).
T Cell Contact Residues of the HEL-(20-35) Epitope--
To
identify the TCR contact residues involved in the recognition of the
HEL-(20-35) epitope, we evaluated the response of 11 HEL-(20-35)-specific T cell hybridomas to Ala-substituted peptides. The T cell recognition of all the T hybridomas was completely abolished
when the Trp at position 28 was changed to Ala. A similar response was
observed for the Ala-substituted
HEL-(20-35) Ala-25 peptide (Fig.
8 and Table I). On the basis
that the HEL-(20-35) Ala-25 and Ala-28 peptides bind to
I-Ak molecule as well as the HEL-(20-35) peptide, we can
state with confidence that residues Leu-25 (P2) and Trp (P5) are
obligatory TCR contacts. The Ala substitution of Tyr-23 (P
1)
had an effect on T cell recognition; 6 of 11 T cell hybridomas did not
respond to the HEL-(20-35) Ala-23 peptide, indicating that residues
outside the core peptide (HEL-(24-32)) can influence the T cell
recognition (11). A significant number of T cells (7 of 11) was
sensitive to the change of Val=29 (P6) to Ala. This change did not
reduce the peptide binding to the class II molecule I-Ak,
suggesting that this amino acid substitution on the anchor residue P6
(Val) can alter the display of the HEL-(20-35) peptide affecting the T
cell recognition. The capacity of anchor residues to influence the T
cell responses has been observed previously by other groups and by us
(for example, see Refs. 35 and 36). Cys-30 to Ala improved the T cell
recognition. The Ala-27 substitution that affected binding had minimal
effect in the T cell response; in assays in which the peptide is
present for the entire period, there is little effect unless the
impairment in binding is quite pronounced. Most of the T hybridomas
tested responded better to Ala-substituted HEL-(20-35) Ala-30
peptide than the HEL-(20-35). An explanation for this observation is
the Ala change at position 30 (P7), which increased the binding of the
peptide to I-Ak (Fig. 5).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 8.
Identification of the T cell contact residues
of the HEL-(20-35) epitope. T cell hybridomas specific to the
HEL-(18-33) peptide were tested for reactivity to different
Ala-substituted HEL-(20-35) peptides. T cells (1 × 105) were incubated with M12-Ak APC (0.5 × 105) in the presence of different doses of Ala peptides.
The levels of IL-2 production were evaluated using the
IL-2-dependent cell line, CTLL.
|
|
 |
COMMENTS |
We report the isolation and identification of a minor HEL epitope,
using an antibody capture method followed by its analysis using ESI-MS.
The identification of this HEL peptide family confirmed the usefulness
of this method to isolate, concentrate, and analyze peptides displayed
in low abundance on APC (3). This peptide would have been difficult to
identify with current approaches that directly examine for the peptide
by MS combining with biological activity. Indeed, the binding affinity
of the peptide makes it difficult to detect from diluted mixtures
comprising several molecular species. Some of the critical problems
with the peptide isolation from class II molecules stem from the fact
that a wide range of peptides with different degrees of affinities,
lengths, and compositions binds to the class II molecules. Moreover,
these isolated HEL peptides are presented as a group or family with
several members, which adds to the difficulty of identifying all of
them. The conspicuous observation reported in this study, that the
tyrosine sulfation of the HEL-(20-35) peptides was generated during
the peptide isolation procedure, emphasizes the need to establish that
post-translational modification are present on naturally processed
peptides isolated from APCs.
We are starting to gain an understanding of the chemical basis for
peptide selection by class II MHC molecules during the intracellular processing of the protein (8, 37, 38) (Table II). This understanding is fundamental in determining the
degree of specificity of MHC molecules for peptides and the
relationship between the major selected peptides and their binding and
sequence motifs (8).
The most abundant peptide families selected by I-Ak, both
from natural autologous proteins, and HEL, are made of sequences that
contain acidic residues that interact with the P1 site (forming a
favorable ion pair with an Arg-32 residue from the
-chain). The
acidic peptide residue is usually situated four or five residues from
the first amino-terminal amino acid (17). With HEL, the major peptide
family, 48-63, is selected always in one register (39); this selection of epitope-(48-63) depends on a
vary favorable Asp-52 plus other anchor residues that, without
contributing much to binding strength, favor the interaction of the
entire peptide.
At present, two epitopes found in much lesser amounts have been
identified by us, 20-35 in this study and 31-45 in the previous reports (3, 18), with both having similar features (Table II). The
HEL-(20-35) segment binds with much less strength to I-Ak
than the dominant -(48-61); its most favorable residue, contributing both to the selection and binding, is an Asn, mapped at P4. The structural analysis of I-Ak molecule made by Fremont's
laboratory (34) and the analysis of natural peptides (8) indicated that
the P4 pocket could tolerate small hydrophobic residues but also showed
a preference for asparagines. The asparagines could be favored by their
interactions with a Glu-
74 residue (34). We establish here that
peptides having an Asn that fits into P4, but lacking a strong acidic
residue at P1, bind with less strength and are also selected at much
lesser amounts than those with the favorable P1 acidic residue. Thus, definite chemical distinctions between strong and weak peptides are
emerging as these studies progress. Finally, it is notable that
epitope-(20-35) and -(48-61) are selected independently of each
other, in accordance with previous results with epitope-(31-47) and
-(48-61) (18); the presence of one or the other does not affect the
amount expressed. We had found previously that deletion of
segment-(48-63) did not affect the presentations of the other peptides. Here, as shown in Fig. 7, the impairment of the
20-35 did not affect the presentation of 48-63.
 |
ACKNOWLEDGEMENTS |
We thank Shirley Petzold, Kevin Clark,
Qing-Mei Xie, and Gina Filley for technical assistance, Janet
Casmaer for preparation of the manuscript, and members of our
laboratory for many helpful discussions.
 |
FOOTNOTES |
*
This work was supported by grants from the National
Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported in part by the Consejo Nacional de Ciencia y
Tecnología de México.
To whom correspondence should be addressed: Dept. of Pathology
and Immunology, Washington University School of Medicine, 660 South
Euclid Ave., St. Louis, MO 63110. Tel.: 314-362-7440; Fax: 314-362-4096; E-mail: unanue@pathbox.wustl.edu.
Published, JBC Papers in Press, June 7, 2002, DOI 10.1074/jbc.M202316200
 |
ABBREVIATIONS |
The abbreviations used are:
MHC, major
histocompatibility complex;
HEL, hen egg-white lysozyme;
M12-AkmHEL, cell line transfected with a membrane form of
HEL;
ESI-MS, electrospray tandem mass spectrometry;
MS/MS, tandem mass
spectrometry;
CID, collision-induced dissociation;
EAY, acidic random
polymer-containing tyrosine, poly(Glu-Ala-Tyr);
PAPS, 3'-phosphoadenosine 5'-phosphosulfate;
TPST, tyrosylprotein
sulfotransferase;
APC, antigen-presenting cell;
mAb, monoclonal antibody(s);
ELISA, enzyme-linked immunosorbent assay;
OVA, ovalbumin;
IL-2, interleukin 2;
TCR, T cell receptor.
 |
REFERENCES |
| 1.
|
Chicz, R. M.,
Urban, R. G.,
Lane, W. S.,
Gorga, J. C.,
Stern, L. J.,
Vignali, D. A.,
and Strominger, J. L.
(1992)
Nature
358,
764-768[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Hunt, D. F.,
Michel, H.,
Dickinson, T. A.,
Shabanowitz, J.,
Cox, A. L.,
Sakaguchi, J.,
Appella, E.,
Grey, H. M.,
and Sette, A.
(1992)
Science
256,
1817-1820[Abstract/Free Full Text]
|
| 3.
|
Gugasyan, R.,
Vidavsky, I.,
Nelson, C. A.,
Gross, M. L.,
and Unanue, E. R.
(1998)
J. Immunol.
161,
6074-6081[Abstract/Free Full Text]
|
| 4.
|
Nelson, C. A.,
Roof, R. W.,
McCourt, D. W.,
and Unanue, E. R.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
7380-7386[Abstract/Free Full Text]
|
| 5.
|
Rudensky, A.,
Preston-Hurlburt, P. B.,
al-Ramadi, B. K.,
Rothbard, J.,
and Janeway, C. A., Jr.
(1992)
Nature
359,
429-433[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Vignali, D. A. A.,
Urban, R. G.,
Chicz, R. M.,
and Strominger, J. L.
(1993)
Eur. J. Immunol.
23,
1602-1612[Medline]
[Order article via Infotrieve]
|
| 7.
|
Latek, R. R.,
and Unanue, E. R.
(1999)
Immunol. Rev.
172,
209-222[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Suri, A.,
Vidavsky, I.,
van der Drift, K.,
Kanagawa, O.,
Gross, M. L.,
and Unanue, E. R.
(2002)
J. Immunol.
168,
1235-1243[Abstract/Free Full Text]
|
| 9.
|
Nelson, C. A.,
Petzold, S. J.,
and Unanue, E. R.
(1994)
Nature
371,
250-257[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Nelson, C. A.,
Petzold, S. J.,
and Unanue, E. R.
(1993)
0 Proc. Natl. Acad. Sci. U. S. A.
90,
1227-1235[Abstract/Free Full Text]
|
| 11.
|
Carson, R. T.,
Vignali, K. M.,
Woodland, D. L.,
and Vignali, D. A.
(1997)
Immunity.
7,
387-394[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Vignali, D. A.,
and Strominger, J. L.
(1994)
J. Exp. Med.
179,
1945-1955[Abstract/Free Full Text]
|
| 13.
|
Velazquez, C.,
DiPaolo, R.,
and Unanue, E. R.
(2001)
J. Immunol.
166,
5488-5592[Abstract/Free Full Text]
|
| 14.
|
Peterson, D. A.,
DiPaolo, R. J.,
Kanagawa, O.,
and Unanue, E. R.
(1999)
Immunity
11,
453-459[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Dadaglio, G.,
Nelson, C. A.,
Deck, M. B.,
Petzold, S. J.,
and Unanue, E. R.
(1997)
Immunity
6,
727-735[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Wade, W. F.,
Chen, Z. Z.,
Maki, R.,
McKercher, S.,
Palmer, E.,
Cambier, J. C.,
and Freed, J. H.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
6297-6305[Abstract/Free Full Text]
|
| 17.
|
Nelson, C. A.,
Vidavsky, I.,
Viner, N. J.,
Gross, M. L.,
and Unanue, E. R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
628-636[Abstract/Free Full Text]
|
| 18.
|
Gugasyan, R.,
Velazquez, C.,
Vidavsky, I,
Deck, B. M.,
van der Drift, K.,
Gross, M. L.,
and Unanue, E. R.
(2000)
J. Immunol.
165,
3206-3213[Abstract/Free Full Text]
|
| 19.
|
Pierres, M.,
Devaux, C.,
Dosseto, M.,
and Marchetto, S.
(1981)
Immunogen
14,
481-491[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Latek, R. R.,
Suri, A.,
Petzold, S. J.,
Nelson, C. A.,
Kanagawa, O.,
Unanue, E. R.,
and Fremont, D. H.
(2000)
Immunity
12,
699-707[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Luescher, I. F.,
and Unanue, E. R.
(1985)
J. Immunol. Methods
135,
233-239
|
| 22.
|
Lee, R. W.,
and Huttner, W. B.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
6143-6151[Abstract/Free Full Text]
|
| 23.
|
Nemeth-Cawley, J. F.
(2001)
J. Mass Spectrom.
36,
1301-1311[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Severs, J. C.,
Carnine, M.,
Eguizabal, H.,
and Mock, K. K.
(1999)
Rapid Commun. Mass Spectrom.
13,
1016-1023[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Rappsilber, J.,
Steen, H.,
and Mann, M.
(2001)
J. Mass Spectrom.
36,
832-833[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Zhou, H.,
Watts, J. D.,
and Aebersold, R.
(2001)
Nat. Biotechnol.
19,
375-378[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
McLachlin, D. T.,
and Chait, B. T.
(2001)
Curr. Opin. Chem. Biol.
5,
591-602[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Annan, R. S.,
and Carr, S. A.
(1996)
Anal. Chem.
68,
3413-3421[Medline]
[Order article via Infotrieve]
|
| 29.
|
Qin, J.,
and Chait, B. T.
(1997)
Anal. Chem.
69,
402-4009[CrossRef]
|
| 30.
|
DeGnore, J. P.,
and Qin, J.
(1998)
J. Am. Soc. Mass Spectrom.
9,
1175-1188[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
| Huttner, W. B., and Bauerle, P. A. (1988) in Modern
Cell Biology (Satir, B., ed) Vol. 6, pp. 97-121, New
York
|
| 32.
|
Huttner, W. B.
(1988)
Annu. Rev. Physiol.
50,
363-377[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Baeuerle, P. A.,
and Huttner, W. B.
(1987)
J. Cell Biol.
105,
2655-2663[Abstract/Free Full Text]
|
| 34.
|
Fremont, D. H.,
Monnaie, D.,
Nelson, C. A.,
Hendrickson, W. A.,
and Unanue, E. R.
(1998)
Immunity
8,
305-312[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Kersh, G. J.,
Miley, M. J.,
Nelson, C. A.,
Grakoui, A.,
Horvath, S.,
Donermeyer, D. L.,
Kappler, J.,
Allen, P. M.,
and Fremont, D. H.
(2001)
J. Immunol.
166,
3345-3355[Abstract/Free Full Text]
|
| 36.
|
Peterson, D. A.,
DiPaolo, R. J.,
Kanagawa, O.,
and Unanue, E. R.
(2001)
J. Immunol.
166,
5874-5982[Abstract/Free Full Text]
|
| 37.
|
Rammensee, H. G.,
Friede, T.,
and Stevanovic, S.
(1995)
Immunogenetics
41,
178-183[Medline]
[Order article via Infotrieve]
|
| 38.
|
Falk, K.,
Rotzschke, O.,
Stevanovic, S.,
Jung, G.,
and Rammensee, H. G.
(1991)
Nature
351,
290-293[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Latek, R. R.,
Petzold, S.,
and Unanue, E. R.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
11460-11465[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. G. Levisetti, A. Suri, S. J. Petzold, and E. R. Unanue
The Insulin-Specific T Cells of Nonobese Diabetic Mice Recognize a Weak MHC-Binding Segment in More Than One Form
J. Immunol.,
May 15, 2007;
178(10):
6051 - 6057.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Herzog, Y. Maekawa, T. P. Cirrito, B. S. Illian, and E. R. Unanue
Activated antigen-presenting cells select and present chemically modified peptides recognized by unique CD4 T cells
PNAS,
May 31, 2005;
102(22):
7928 - 7933.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| This Article |
 |
 |
Abstract
|
 |
Full Text (PDF)
|
 |
All Versions of this Article:
277/45/42514
most recent
M202316200v1
|
 |
| |